Interventions of Interest: Abaloparatide (Tymlos®, Radius Health, Inc.) Teriparatide (Forteo®, Eli Lilly and Co.) Osteoporosis, the weakening of the bones through loss of bone mineral content and a decrease in bone quality, is a common disease of aging that affects approximately 10 million Americans. Approximately half of women and one quarter of men will suffer […]
Palliative care is a management approach that provides symptom relief and comfort care to patients with serious or life-threatening illnesses, with the goal of improving quality of life for both patients and their families. Unlike hospice care, which is typically restricted to individuals with a prognosis of survival of six months or less, palliative care can begin at […]
Treatments of Interest: peanut immunotherapy (Viaskin® Peanut, DBV Technologies) peanut immunotherapy (PalforziaTM, Aiummune) Peanut is a common childhood allergen in the United States (US). According to recent estimates approximately 1.4-4.5% of children suffer from peanut allergy. It is more common in males (1.7% versus 0.8%), people with lower income (1.7% versus 1.2%), and there are […]
Interventions of Interest: Intensity modulated radiation therapy for prostate cancer Prostate cancer is the most common nondermatologic cancer in men. In 2006, approximately230,000 new patients in the United States were diagnosed with prostate cancer and 27,000 men died of the disease. The major treatment options for localized prostate cancer include external beam radiation therapy, brachytherapy, […]
Interventions of Interest: Brachytherapy and Proton beam therapy for prostate cancer. Prostate cancer is the second leading cause of cancer deaths and the seventh overall causeof death in men in the United States (Centers for Disease Control and Prevention, 2008).Given that most new cases are diagnosed at an early, localized stage, significant attentionhas been focused […]
ICER developed a report on Active Surveillance and Radical Prostatectomy for prostate cancer. Prostate cancer is the second leading cause of cancer deaths and the seventh overall causeof death in men in the United States (Centers for Disease Control and Prevention, 2008).Given that most new cases are diagnosed at an early, localized stage, significant attentionhas […]
Interventions of Interest: enzalutamide (Xtandi®, Astellas and Medivation) abiraterone acetate (Zytiga®, Janssen) apalutamide (Erleada™, Janssen). October 2018 Review ICER developed a report on anti-androgen drugs for high risk prostate cancer. The added costs of treating earlier stage disease with all therapies are aligned with their added clinical benefits for patients. For questions or additional information, […]
Intervention of interest: Proton beam therapy ICER completed a Technology Assessment of proton beam therapy (PBT) for the public meeting of the Washington State Health Care Authority Clinical Committee. ICER’s review found that PBT was superior to surgical treatment of tumors of the eye, and appears to be a safer alternative to conventional radiation in […]
Interventions of Interest: Crizanlizumab (Adakveo®, Novartis) Voxelotor (Oxbryta®, Global Blood Therapeutics) L-gluatmine (Endari, Emmaus Medical) Due to the COVID-19 pandemic, we have decided to indefinitely postpone our public meeting on therapies for sickle cell disease (originally slated for March 26, 2020). Please refer to the sickle cell disease evidence report for our most updated findings. […]
Interventions of Interest: Valbenazine (Ingrezza®, Neurocrine Biosciences, Inc) Deutetrabenazine (Austedo®, Teva) Tetrabenazine (Xenazine®, Ovation Pharmaceuticals) Tardive dyskinesia is a serious and disabling movement disorder that affects individuals treated with antipsychotic agents for a variety of mental health conditions. Though prevention and treatment primarily focus on stopping or changing the offending antipsychotic agent, for some individuals […]